Background : Cellular drug resistance is supposed to play a major role in chemotherapy failure or relapse. The purpose of this study was to analyze the relationship between in vitro chemosensitivity test results using a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay and clinical response on chemotherapy, and to find the possibility of optimizing the treatment protocol for individual patients according to their actual drug resistance.
INTRODUCTION
Despite current combination chemotherapy, 50% of the acute lymphoblastic leukemia (ALL) patients relapse after achieving initial remission, 20% of acute myeloid leukemia (AML) do not respond to induction chemotherapy, and 40-60% of responsive AML relapse [1] . Drug resistance is considered to be a major cause of these chemotherapy failures. It is unknown to which drugs and to what extent resistance occurs. It is difficult to isolate a single drug that causes the resistance, because of the multidrug regimen.
Cell culture drug resistance assay would facilitate the identification of a single resistant drug. Many studies on in vitro chemosensitivity assays have been performed with established cell lines [2] . The clonogenic assays have successfully been used to predict initial response to chemotherapy in AML patients, but technical problems and the long culturing time have limited the clinical use of the method [2] . Most assays in use are short term total cell killing assays, where the culturing procedure is essentially the same but the methods to determine viable cells after culturing are different. In the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, the surviving cells convert MTT into formazan, which can be quantified by spectrophotometry [2, 3] . Compared with other in vitro chemosensitivity tests, the MTT assay is a short-term assay (2-4 days) and uses a very low number of cells in suspension. Because of its high efficiency, the assay is currently used in determining the chemosensitivity of cell lines [4] [5] [6] [7] [8] [9] .
The purpose of this study was to evaluate whether the MTT assay can be utilized as an in vitro chemosensitivity test, and to optimize the treatment protocol according to the actual drug resistance in acute leukemia patients.
MATERIALS AND METHODS

Patients
The bone marrow samples were collected from 103 patients with acute leukemia in Asan Medical Center, including AML (N=64), ALL (N=33) and acute mixed lineage leukemia (AMLL) (N=6) ( Table 1) for child patients with ALL.
Culture medium and culture suspension
The samples were finally resuspended in culture medium containing RPMI-1640, 15% fetal calf serum, 1% Lglutamine, 100 IU/mL penicillin, and 100 g/mL streptomycin (Gibco Co, Grand Island, NY, USA). The cell concentration for the MTT assay was finally adjusted to 1×10 6 cells/mL.
MTT assay
The 
Drugs tested
L-asparaginase (L-ASP), and mitoxantrone (MIT) were tested. These drugs were selected because AraC, DNR, and MIT are usually given to AML patients and VCR, Dexa, DNR, L-ASP, and MTX are given to ALL patients according to protocol. Dexa was dissolved in saline, and DNR was dissolved in distilled water. The other drugs were dissolved in solutions ready for use. All drugs were further diluted with RPMI-1640. The concentrations of drugs are given in Table 2 . In this study, drug concentrations were chosen to mimic the in vivo situation [12, 13] .
6. Criteria for the response of in vitro chemosensitivity using MTT assay 
Statistics
The relationship between the MTT assay results and the clinical responses was tested for statistical significance using appropriate t-test and chi-square test. The KaplanMeier method was used to estimate survival distribution, and a log rank test was used to analyze differences between groups. A P value less than 0.05 was considered to be significant. All analyses were performed using the SPSS 11.5 software package (SPSS, Chicago, IL, USA). (Table 3 ).
RESULTS
Clinical course of patients
MTT sensitivity test and clinical outcomes after chemotherapy
For both adult and childhood ALL, patients showing sensitivity to DNR had a higher CR rate. However, the mean MTT dead cell percentages for each drug were not significantly related to the CR rate in patients with AML.
The relationship between the MTT assay results of combination drugs and the clinical response of induction chemotherapy is summarized in Table 4 and Fig. 1 . For childhood ALL, many patients with MTT results in the S category achieved CR after induction chemotherapy (Table 4 , P=0.011). For AML, patients with results in the S category tended to maintain continuous CR, and patients in the I and R categories tended to undergo relapse (Fig. 1, P=0 .010). The MTT assay results and the period of disease free survivals or overall survivals were not significantly related. Differences of mean MTT dead cell percentages between samples at initial diagnosis and those at relapse were not statistically significant.
DISCUSSION
This study was designed to evaluate the predictive value of an MTT in vitro assay for the assessment of leukemic *S, sensitive to all of two drugs (AraC, DNR); I, sensitive to one of two drugs; R, sensitive to none of two drugs. Table 3 . Long-term outcomes of patients with acute leukemia (N=103) cell susceptibility to 7 chemotherapeutic drugs, and to compare these results with clinical response in 103 cases of acute leukemia.
In many patients, a temporary phase of clinical remission is followed by a relapse primarily consisting of chemoresistant tumor cells, which is frequently associated with clinically refractory disease. This may be caused by unfavorable cytogenetic of leukemic cells, lack of expected pharmacokinetics, cellular drug resistance, pharmacological resistance, and the persistence of minimal residual disease [5, 14, 15] . Cellular drug resistance is supposed to play a major role in chemotherapy failures of both newly diagnosed cases and relapse cases of acute leukemia [8, 9] . A more detailed insight regarding drug resistance may be used as a rationale to develop more effective treatment regimens for such patients.
In spite of the fact that in vitro chemosensitivity testing in acute leukemia has been studied for many years In several previous studies, the association between values of MTT sensitivity and clinical response to chemotherapy was shown [16, 17] . Moreover, the chemosensitivity of samples at diagnosis of ALL was identified to be as an important prognostic factor for disease free survival [18, 19] . In this study, it was also found that a relationship between in vitro chemosensitivity of drug and clinical response after induction chemotherapy in patients with childhood ALL exists ( Table 4 , P=0.011). Another finding showed that in vitro sensitivity of lymphoblasts to DNR is significantly related to the clinical response in both adult and childhood ALL.
For AML, high in vitro drug resistance could partially explain unfavorable clinical results of therapy, when compared to ALL [1, 20] . One of the reasons for the poor therapeutic outcomes may be cellular drug resistance to chemotherapy. In this study, in vitro chemosensitivity is significantly related to continuous complete remission or relapse (Fig. 1, P=0 .010). However, differences in each drug sensitivity were not significant between clinical responder and nonresponder in both this study and other studies [20] .
It is commonly assumed that relapsed patients are more drug resistant than those initially diagnosed. The results of this study showed that there were no differences in MTT assay results between samples taken at diagnosis and at relapse for both AML and ALL. In other studies for AML [5, 14] , no significant differences were reported as well. In general, relapsed AML has a dismal prognosis, which is largely associated to the length of the timeinterval between initial diagnosis and relapse. It seems that factors other than cellular drug resistance can play a key role in failure of relapsed AML therapy. However, in other ALL studies, lymphoblasts from children with relapsed ALL were more resistant in vitro to most front line drugs when compared with those of a historical control group of children with newly diagnosed ALL [6] . 
